ACE Inhibitors: Clinical Guide
ACE inhibitors are first-line therapy for heart failure with reduced ejection fraction, post-myocardial infarction with LV dysfunction, diabetic nephropathy, and hypertension with diabetes or coronary artery disease, with proven mortality reduction across these conditions.
Indications
Class I (Strongest Evidence)
Heart Failure with Reduced Ejection Fraction (HFrEF)
- All symptomatic patients with LVEF ≤40% should receive ACE inhibitors indefinitely 1, 2, 3
- Even asymptomatic patients with documented LV systolic dysfunction benefit from long-term therapy 1
- Reduces mortality, hospitalizations, and improves functional capacity 1, 2
Post-Myocardial Infarction
- Start early in all patients with signs/symptoms of heart failure after acute MI, even if transient 1
- Mandatory in patients with anterior MI, previous MI, or Killip class II findings 4, 5
- Continue indefinitely in all post-MI patients with LVEF ≤40% 4, 5
Diabetic Nephropathy
- First-line for type 1 diabetic nephropathy 6
- Type 2 diabetic nephropathy with microalbuminuria or proteinuria 6, 7
- Reduces progression to overt nephropathy by 24% 6
Coronary Artery Disease with Diabetes
- All patients with CAD (documented by angiography or previous MI) who have diabetes should receive ACE inhibitors 6
- Reduces cardiovascular death by 37%, MI by 22%, and stroke by 33% 6
Class IIa (Reasonable)
- All patients with CAD or other vascular disease, even without diabetes 6
- Lower-risk patients with normal LVEF after revascularization 4, 5
- Hypertension management, particularly with target organ damage 8, 9
Dosing
Starting and Target Doses
Always start low and titrate to target doses proven in clinical trials 1, 2, 3:
| Drug | Starting Dose | Target Dose |
|---|---|---|
| Enalapril | 2.5 mg twice daily | 10-20 mg twice daily |
| Lisinopril | 2.5-5 mg once daily | 20-40 mg once daily |
| Ramipril | 1.25-2.5 mg once daily | 10 mg once daily |
| Captopril | 6.25 mg three times daily | 50 mg three times daily |
| Perindopril | 2 mg once daily | 8-16 mg once daily |
| Trandolapril | 1 mg once daily | 4 mg once daily |
Titration Protocol 1, 2
- Start at lower dose level
- Increase dose every 1-2 weeks if tolerated
- Target the maximum doses used in clinical trials—these are the doses that saved lives
- Do not stop at lower doses just because symptoms improve
Critical Point: The mortality benefit in trials was achieved at target doses, not at symptom-controlled doses 3.
Monitoring
Renal Function and Electrolytes 1, 2
Check creatinine and potassium:
- Before starting
- 1-2 weeks after each dose increment
- At 3-6 month intervals during maintenance
- When adding other RAAS agents (ARB, aldosterone antagonist)
- During any hospitalization
Acceptable Changes 2
- Modest creatinine increase (up to 20%) is expected and acceptable
- eGFR decrease up to 15% is tolerable
- Small blood pressure reductions are normal in normotensive patients
When to Discontinue or Reduce Dose 2
- eGFR decreases >15%
- Creatinine increases >20%
- Potassium >5.5 mEq/L
- Symptomatic hypotension unresponsive to dose adjustment
Contraindications
Absolute (Class III) 1, 2
- Bilateral renal artery stenosis
- History of angioedema with previous ACE inhibitor therapy
- Pregnancy (all trimesters)
- Current angioedema from any cause
Relative Cautions 9, 10
- Severe renal impairment (creatinine >2.5 mg/dL in men, >2.0 mg/dL in women)
- Baseline potassium >5.0 mEq/L
- Severe aortic stenosis
- Hypotension (SBP <90 mmHg)
Adverse Effects
Common (5-10% of patients) 1, 2
Dry Cough
- Occurs in 5-10% of patients, more common in Chinese patients (up to 50%) 2
- Nonproductive with persistent throat "tickle"
- Appears within first months of therapy
- Disappears 1-2 weeks after discontinuation
- Management: Exclude pulmonary congestion first; if cough is tolerable, continue therapy given mortality benefit; if intolerable, switch to ARB 2
Hypotension
- Usually small decreases in normotensive patients 1
- More common with first dose in volume-depleted patients
- Management: Ensure adequate hydration, reduce diuretic dose temporarily, give ACE inhibitor at bedtime
Hyperkalemia
- Monitor closely, especially with concurrent aldosterone antagonists or ARBs 2
- Risk increases with renal dysfunction
Serious but Rare (<1%) 2
Angioedema
- Life-threatening emergency
- More frequent in Black patients
- Absolute contraindication to all future ACE inhibitor use
- ARBs may be used with extreme caution (cross-reactivity possible) 2
Renal Insufficiency
- Acute worsening possible, especially with bilateral renal artery stenosis
- Usually reversible with discontinuation
Hypoglycemia 10
- Not widely recognized but can occur in patients on glucose-lowering medications
- Monitor glucose more closely when initiating ACE inhibitors in diabetics
Alternatives When ACE Inhibitors Not Tolerated
First Alternative: Angiotensin Receptor Blockers (ARBs) 2, 5
Use ARBs if:
- Intolerable cough on ACE inhibitor (Class I indication) 1, 2
- Angioedema on ACE inhibitor (use with extreme caution—cross-reactivity possible) 2
- LVEF ≤40% with heart failure or post-MI 5
- Candesartan: 4-8 mg once daily, target 32 mg once daily
- Losartan: 25-50 mg once daily, target 50-100 mg once daily
- Valsartan: 20-40 mg twice daily, target 160 mg twice daily
Important: ARBs have similar risks of hypotension, hyperkalemia, and renal dysfunction as ACE inhibitors 2. Angioedema is much less frequent but still possible 2.
Second Alternative: Hydralazine-Isosorbide Dinitrate 2, 3
Use if ACE inhibitors AND ARBs are contraindicated or not tolerated 2
Dosing 3:
- Start: 20 mg isosorbide dinitrate + 37.5 mg hydralazine three times daily
- Target: 40 mg isosorbide dinitrate + 75 mg hydralazine three times daily
Special consideration: Particularly effective in Black patients with NYHA class III-IV heart failure (43% mortality reduction) 3
Third Alternative: Angiotensin Receptor-Neprilysin Inhibitor (ARNi) 11, 3
Sacubitril-valsartan is now preferred over ACE inhibitors for HFrEF 11, 3:
- Start: 49 mg sacubitril/51 mg valsartan twice daily
- Target: 97 mg sacubitril/103 mg valsartan twice daily
- Provides 16% additional mortality reduction beyond ACE inhibitors 3
- Do not use within 36 hours of last ACE inhibitor dose (angioedema risk)
Combination Therapy Considerations
ACE Inhibitor + ARB 2, 8
Not routinely recommended 2, 8
- May modestly reduce hospitalizations 2
- Increases risk of hypotension, hyperkalemia, and renal dysfunction 8
- If used, requires careful monitoring 8
- Never combine all three: ACE inhibitor + ARB + aldosterone antagonist 2
ACE Inhibitor + Beta-Blocker + Aldosterone Antagonist + SGLT2 Inhibitor 11, 3
This is the current "four pillars" approach for HFrEF 11, 3:
- All four should be initiated and titrated rapidly
- Each provides independent mortality benefit
- Monitor potassium and renal function closely with aldosterone antagonist added
Special Populations
Renal Impairment 1, 10, 12
- Dose reduction required when creatinine clearance <30 mL/min 12
- Exception: Fosinopril has dual hepatic/renal elimination—may not require dose adjustment 12, 13
- Lisinopril preferred in liver disease (renal excretion only) 12
Acute Heart Failure 1, 13
- Initiate carefully with low doses
- Maintain or add diuretic therapy
- Captopril may be preferred for first-dose due to rapid onset and short duration (allows quick reversal if hypotension occurs) 13
Diabetes with CKD 7, 10, 14
- ACE inhibitors remain first-line unless severe renal dysfunction
- Contraindicated if creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women) 5
- Monitor for hypoglycemia 10
Key Clinical Pearls
Target doses matter: Don't settle for symptom control at low doses—titrate to trial-proven target doses for mortality benefit 3
Cough is common but manageable: Encourage continuation if tolerable given survival benefit; only switch to ARB if truly intolerable 2
Modest creatinine rise is acceptable: Up to 20% increase is expected and does not require discontinuation 2
Angioedema is absolute contraindication: Never rechallenge with any ACE inhibitor; use ARBs with extreme caution 2
Start early post-MI: Initiate within days of MI in appropriate patients for maximum benefit 1, 4
Monitor potassium closely: Especially when combining with aldosterone antagonists or in renal impairment 1, 2
ARNi is now preferred over ACE inhibitors for HFrEF when tolerated 11, 3